Skip to ContentSkip to Navigation
How to find us prof. dr. H.J. (Hiddo) Lambers Heerspink


A novel drug response score more accurately predicts renoprotective drug effects than existing renal risk scores

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial

Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF

Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease

HDL particle subspecies and their association with incident type 2 diabetes: the PREVEND study

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting

Read more


Canagliflozin May Reduce Anemia Risk in Diabetic CKD

Geneesmiddel verlengt levensverwachting bij patiënten met nierfalen

Positief effect diabetesmedicatie op nierfunctie direct toepasbaar in klinische praktijk

Pil die nieren spaart bij suikerziekte

Diabetes type 1,2,3,4 en 5: op weg naar gepersonaliseerde behandeling

Intervieuw Diabetes Fonds Dialoog

De Route van hoogleraar Hiddo Lambers Heerspink

Read more